Results 141 to 150 of about 169,027 (313)
A colloid approach to self-assembling antibodies [PDF]
arXiv, 2018 Concentrated solutions of monoclonal antibodies have attracted considerable attention due to their importance in pharmaceutical formulations, yet their tendency to aggregate and the resulting high solution viscosity has posed considerable problems.
arxiv
Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. [PDF]
, 2019 The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and ...
Le, Catherine T, Murphy, William J
core +1 more source
Chronic Diseases and Translational Medicine, EarlyView.Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash +1 more
wiley +1 more source
Amyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele
Chronic Diseases and Translational Medicine, EarlyView.Mechanism of action of monoclonal antibodies targeting Aβ in the treatment of AD. (A) Targets of various mAbs. (B) Mechanism of monoclonal antibody‐mediated clearance of Aβ. mAbs facilitate the clearance of Aβ by enhancing microglial‐mediated phagocytosis through the upregulation of TREM2 expression.
Valentinus Besin +5 more
wiley +1 more source
Mathematical Model of Colorectal Cancer with Monoclonal Antibody Treatments [PDF]
arXiv, 2013 We present a new mathematical model of colorectal cancer growth and its response to monoclonal-antibody (mAb) therapy. Although promising, most mAb drugs are still in trial phases, and the possible variations in the dosing schedules of those currently approved for use have not yet been thoroughly explored.
arxiv
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
Clinical Pharmacology &Therapeutics, EarlyView.Oncology dose optimization during the era of chemotherapy focused on identifying the maximum tolerated dose (MTD) for registrational trials, often resulting in significant toxicity. The advent of molecular targeted drugs and immunotherapies offers the potential to achieve similar efficacy with lower doses and fewer side effects, as maximal efficacy is ...
Jiawen Zhu +12 more
wiley +1 more source
An Asymptotic Analysis of Bivalent Monoclonal Antibody-Antigen Binding [PDF]
arXivLigand-receptor interactions are fundamental to many biological processes. For example in antibody-based immunotherapies, the dynamics of an antibody binding with its target antigen directly influence the potency and efficacy of monoclonal antibody (mAb) therapies.
arxiv
Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs [PDF]
arXiv, 2019 Four randomized placebo-controlled efficacy trials of a candidate vaccine or passively infused monoclonal antibody for prevention of HIV-1 infection are underway (HVTN 702 in South African men and women; HVTN 705 in sub-Saharan African women; HVTN 703/HPTN 081 in sub-Saharan African women; HVTN 704/HPTN 085 in U.S., Peruvian, Brazilian, and Swiss men ...
arxiv
Clinical Pharmacology &Therapeutics, EarlyView.Riliprubart is a second‐generation, humanized immunoglobulin G4 that inhibits only the activated form of the C1s component of the proximal classical complement pathway. The clinical studies of riliprubart conducted thus far for the treatment of cold agglutinin disease (CAD), a rare autoimmune disease, include a Phase 1 first‐in‐human study in healthy ...
Timothy Chow +3 more
wiley +1 more source
SQUID Magnetometry for Cancer Screening a Feasibility Study [PDF]
arXiv, 2003 The recent demonstration that nanoparticles associated with various biological molecules and pharmacological agents can be administered systemically to humans, without toxicity from the particles, has opened a new era in the targeting of such particles to specific tissues in the body for the imaging and therapy of disease.
arxiv